<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936377</url>
  </required_header>
  <id_info>
    <org_study_id>09-0406</org_study_id>
    <nct_id>NCT00936377</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal</brief_title>
  <acronym>DATA</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate dexmedetomidine as adjunctive therapy of severe alcohol
      withdrawal of medical ICU patients. Specifically, this study will assess whether adjunctive
      dexmedetomidine reduces the doses of conventional agents used for alcohol withdrawal while
      maintaining patient comfort and safety and will explore if dexmedetomidine exhibits a
      dose-dependent profile of action when it is used for this indication. In addition, this study
      will assess the relationships between alcohol withdrawal, therapy with dexmedetomidine, and
      potential serum biomarkers of alcohol withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this randomized, double-blind, placebo controlled, dose escalation study
      are a) to determine if adding dexmedetomidine to symptom-triggered, standard therapy of
      severe alcohol withdrawal reduces the dose requirements of conventional sedatives,
      analgesics, and neuroleptics; maintains patient comfort and safety; and prevents and shortens
      tracheal intubation; b) to explore whether dexmedetomidine acts in a dose-dependent manner to
      reduce the dose requirements of conventional sedatives, analgesics, and neuroleptics while
      maintaining patient comfort; and c) determine the association between alcohol withdrawal and
      potential serum biomarkers of alcohol withdrawal and assess whether these are expressed
      differently when dexmedetomidine is used as adjunctive therapy. Dexmedetomidine will be added
      to existing sedative therapies in an effort to decrease the use of these agents while
      maintaining patient comfort. The study will randomize twenty-four patients in a double-blind
      manner to receive placebo or dexmedetomidine at doses of 0.4 or 1.2 µg/kg per hour for a
      maximum duration of five days. All patients will be managed using an existing
      institution-specific, symptom-triggered alcohol withdrawal protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal</measure>
    <time_frame>Seven days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 12-Hour Lorazepam Requirement Pre- and Post-Treatment</measure>
    <time_frame>12 hours before treatment, 12 hours after treatment on first day of starting study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 24-Hour Lorazepam Requirement Pre- and Post-Treatment</measure>
    <time_frame>24 hours before treatment, 24 hours after treatment on first day of starting study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Degree of Alcohol Withdrawal Assessed by Clinical Institute Withdrawal Assessment (CIWA) Scores</measure>
    <time_frame>Every 2-4 hours for 24 hours after starting study drug</time_frame>
    <description>Proportion of clinical institute withdrawal assessment (CIWA) Scores listed as severe or moderate 24 Hours after Starting Study Drug. All subjects had at least four CIWA assessments.The CIWA is a ten item scale with each item on the scale scored independently on a 0-7 or 0-4 scale, and the summation of the scores yielding an aggregate value that correlates to the severity of alcohol withdrawal. Ranges of scores are from 0 to 67. Mild alcohol withdrawal is defined with a score less than or equal to 15, moderate with scores of 16 to 20, and severe with any score greater than 20. The ten items evaluated include nausea and vomiting, tremor, sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Occurrence of Adverse Events.</measure>
    <time_frame>Seven days</time_frame>
    <description>Occurrence of hypotension or bradycardia while on study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Epinephrine Concentrations Across Groups Over Time</measure>
    <time_frame>Four days with samples measured prior to study drug and 48 and 96 hours after starting study drug</time_frame>
    <description>Plasma epinephrine concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Study Drug Administration</measure>
    <time_frame>The duration of study drug in hours as measured when the subject was discharged from the ICU, for up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>The duration of ICU stay in days as measured at time of hospital discharge, for up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Acute Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
    <arm_group_label>Dexmedetomidine, low dose</arm_group_label>
    <arm_group_label>Dexmedetomidine, high dose</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline for five days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe alcohol withdrawal defined by a CIWA score ≥ 15 and the need for at least 16 mg
             of lorazepam over a four-hour period. All lorazepam doses, whether oral or
             intravenous, will contribute to the cumulative amount.

          2. Patients receiving standard therapy for severe alcohol withdrawal according to a
             symptom-triggered alcohol withdrawal protocol. Lorazepam is the preferred
             benzodiazepine agent for patients requiring ICU admission due to alcohol withdrawal.

          3. Informed consent within 36 hours of qualifying for the study.

        Exclusion Criteria:

          1. Patients &lt; 18 years of age or &gt; 85 years of age.

          2. Patients receiving benzodiazepine therapy for purposes other than alcohol withdrawal
             (e.g. sedation).

          3. Patients with alcohol withdrawal not requiring ICU admission.

          4. Patients receiving epidural administration of medication(s).

          5. Comatose patients by metabolic or neurologic affectation.

          6. Patients with active myocardial ischemia or second- or third-degree heart block.

          7. Moribund state with planned withdrawal of life support.

          8. Patients with known or suspected severe adverse reactions to dexmedetomidine (or
             clonidine).

          9. Pregnant females or females suspected of being pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert MacLaren, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <results_first_submitted>March 9, 2016</results_first_submitted>
  <results_first_submitted_qc>April 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2016</results_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine, Low Dose</title>
          <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine, High Dose</title>
          <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Normal saline
Placebo: Normal saline for five days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine, Low Dose</title>
          <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine, High Dose</title>
          <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Normal saline
Placebo: Normal saline for five days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="28" upper_limit="60"/>
                    <measurement group_id="B2" value="50" lower_limit="30" upper_limit="56"/>
                    <measurement group_id="B3" value="51" lower_limit="30" upper_limit="61"/>
                    <measurement group_id="B4" value="49.3" lower_limit="28" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.1" lower_limit="44.5" upper_limit="126"/>
                    <measurement group_id="B2" value="84.5" lower_limit="60" upper_limit="126"/>
                    <measurement group_id="B3" value="81.5" lower_limit="58" upper_limit="98"/>
                    <measurement group_id="B4" value="84.4" lower_limit="44.5" upper_limit="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acute Physiologic And Chronic Health Evaluation (APACHE) III</title>
          <description>APACHE III measures the severity of disease for adult patients admitted to intensive care units. The point score is calculated as a summation from scores assigned to a patient's age, primary comorbidity, preexisting comorbidities, location prior to ICU admission, Glasgow Coma Scale, and 20 routine physiological measurements. APACHE III scores range from 0 to 299. This provides an initial risk classification of severely ill hospitalized patients in defined groups with higher scores indicating greater disease severity and correlated to higher mortality risk.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" lower_limit="65" upper_limit="72"/>
                    <measurement group_id="B2" value="56.5" lower_limit="43" upper_limit="64"/>
                    <measurement group_id="B3" value="49.5" lower_limit="30" upper_limit="68"/>
                    <measurement group_id="B4" value="58.5" lower_limit="30" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Endotracheal Intubation at Study Entry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Intubated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not intubated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child-Pugh Score</title>
          <description>The Child-Pugh score is used to assess the prognosis of chronic liver disease. The point score is calculated from the summation of points assigned for total bilirubin (serum), albumin (serum), prothrombin time, and the presence of ascites and encephalopathy. The range is from 0 to 15. Grade A liver disease (scores of 5-6) predict two-year survival of 85%. Grade B liver disease (scores of 7-9) predict two-year survival of 55%. Grade C liver disease (scores of 10-15) predict two-year survival of 35%.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="B2" value="6" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="B3" value="6" lower_limit="5" upper_limit="11"/>
                    <measurement group_id="B4" value="6.3" lower_limit="5" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lorazepam requirement 24 Hour Prior to Study Entry</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94" lower_limit="52" upper_limit="148"/>
                    <measurement group_id="B2" value="75" lower_limit="28" upper_limit="190"/>
                    <measurement group_id="B3" value="39" lower_limit="31" upper_limit="91"/>
                    <measurement group_id="B4" value="69.3" lower_limit="28" upper_limit="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Study Qualification to Study Drug Start</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.1" lower_limit="6.5" upper_limit="33.7"/>
                    <measurement group_id="B2" value="13.5" lower_limit="3.4" upper_limit="27"/>
                    <measurement group_id="B3" value="10.4" lower_limit="1.7" upper_limit="19.9"/>
                    <measurement group_id="B4" value="14" lower_limit="1.7" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal</title>
        <time_frame>Seven days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine, Low Dose</title>
            <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine, High Dose</title>
            <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline
Placebo: Normal saline for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal</title>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.5" lower_limit="79.3" upper_limit="223.4"/>
                    <measurement group_id="O2" value="112.5" lower_limit="48.8" upper_limit="746.8"/>
                    <measurement group_id="O3" value="109.1" lower_limit="40.9" upper_limit="227.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in 12-Hour Lorazepam Requirement Pre- and Post-Treatment</title>
        <time_frame>12 hours before treatment, 12 hours after treatment on first day of starting study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine, Low Dose</title>
            <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine, High Dose</title>
            <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline
Placebo: Normal saline for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 12-Hour Lorazepam Requirement Pre- and Post-Treatment</title>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.5" lower_limit="-52.7" upper_limit="-1.6"/>
                    <measurement group_id="O2" value="-34.3" lower_limit="-61.9" upper_limit="-14.5"/>
                    <measurement group_id="O3" value="-17.5" lower_limit="-24.3" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in 24-Hour Lorazepam Requirement Pre- and Post-Treatment</title>
        <time_frame>24 hours before treatment, 24 hours after treatment on first day of starting study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine, Low Dose</title>
            <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine, High Dose</title>
            <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline
Placebo: Normal saline for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-Hour Lorazepam Requirement Pre- and Post-Treatment</title>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.1" lower_limit="-118" upper_limit="-8.8"/>
                    <measurement group_id="O2" value="-45" lower_limit="-68.9" upper_limit="-16.8"/>
                    <measurement group_id="O3" value="-8" lower_limit="-31.3" upper_limit="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Degree of Alcohol Withdrawal Assessed by Clinical Institute Withdrawal Assessment (CIWA) Scores</title>
        <description>Proportion of clinical institute withdrawal assessment (CIWA) Scores listed as severe or moderate 24 Hours after Starting Study Drug. All subjects had at least four CIWA assessments.The CIWA is a ten item scale with each item on the scale scored independently on a 0-7 or 0-4 scale, and the summation of the scores yielding an aggregate value that correlates to the severity of alcohol withdrawal. Ranges of scores are from 0 to 67. Mild alcohol withdrawal is defined with a score less than or equal to 15, moderate with scores of 16 to 20, and severe with any score greater than 20. The ten items evaluated include nausea and vomiting, tremor, sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation.</description>
        <time_frame>Every 2-4 hours for 24 hours after starting study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine, Low Dose</title>
            <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine, High Dose</title>
            <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline
Placebo: Normal saline for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Degree of Alcohol Withdrawal Assessed by Clinical Institute Withdrawal Assessment (CIWA) Scores</title>
          <description>Proportion of clinical institute withdrawal assessment (CIWA) Scores listed as severe or moderate 24 Hours after Starting Study Drug. All subjects had at least four CIWA assessments.The CIWA is a ten item scale with each item on the scale scored independently on a 0-7 or 0-4 scale, and the summation of the scores yielding an aggregate value that correlates to the severity of alcohol withdrawal. Ranges of scores are from 0 to 67. Mild alcohol withdrawal is defined with a score less than or equal to 15, moderate with scores of 16 to 20, and severe with any score greater than 20. The ten items evaluated include nausea and vomiting, tremor, sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation.</description>
          <units>percentage of ciwa assessment</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage of CIWA scores rates as severe</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>Percentage of CIWA scores rates as severe</p_value_desc>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <p_value_desc>Percentage of CIWA scores rates as severe</p_value_desc>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Occurrence of Adverse Events.</title>
        <description>Occurrence of hypotension or bradycardia while on study drug</description>
        <time_frame>Seven days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine, Low Dose</title>
            <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine, High Dose</title>
            <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline
Placebo: Normal saline for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Occurrence of Adverse Events.</title>
          <description>Occurrence of hypotension or bradycardia while on study drug</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For hypotension</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For hypotension</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For bradycardia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For bradycardia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Epinephrine Concentrations Across Groups Over Time</title>
        <description>Plasma epinephrine concentrations</description>
        <time_frame>Four days with samples measured prior to study drug and 48 and 96 hours after starting study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine, Low Dose</title>
            <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine, High Dose</title>
            <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline
Placebo: Normal saline for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Epinephrine Concentrations Across Groups Over Time</title>
          <description>Plasma epinephrine concentrations</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.17"/>
                    <measurement group_id="O2" value="0.29" spread="0.1"/>
                    <measurement group_id="O3" value="0.31" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.47"/>
                    <measurement group_id="O2" value="0.21" spread="0.09"/>
                    <measurement group_id="O3" value="0.27" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 96 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.33"/>
                    <measurement group_id="O2" value="0.27" spread="0.17"/>
                    <measurement group_id="O3" value="0.3" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Repeated measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Study Drug Administration</title>
        <time_frame>The duration of study drug in hours as measured when the subject was discharged from the ICU, for up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine, Low Dose</title>
            <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine, High Dose</title>
            <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline
Placebo: Normal saline for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Study Drug Administration</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" lower_limit="39.4" upper_limit="89.5"/>
                    <measurement group_id="O2" value="78" lower_limit="22.1" upper_limit="112.5"/>
                    <measurement group_id="O3" value="70.3" lower_limit="25" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Length of Stay</title>
        <time_frame>The duration of ICU stay in days as measured at time of hospital discharge, for up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine, Low Dose</title>
            <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine, High Dose</title>
            <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Normal saline
Placebo: Normal saline for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2.5" upper_limit="9.9"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.4" upper_limit="10"/>
                    <measurement group_id="O3" value="4" lower_limit="1.9" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine, Low Dose</title>
          <description>Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine, High Dose</title>
          <description>Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
Dexmedetomidine: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Normal saline
Placebo: Normal saline for five days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert MacLaren</name_or_title>
      <organization>University of Colorado</organization>
      <phone>303 724-2622</phone>
      <email>rob.maclaren@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

